Valneva (NASDAQ:VALN) Earns Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Valneva (NASDAQ:VALN) in a report released on Friday morning,Benzinga reports. The brokerage currently has a $17.00 price target on the stock.

Valneva Trading Down 1.1 %

NASDAQ VALN opened at $7.17 on Friday. Valneva has a 12 month low of $3.62 and a 12 month high of $9.50. The company has a 50-day moving average of $6.34 and a 200-day moving average of $5.61. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.78 and a quick ratio of 2.25. The company has a market cap of $582.64 million, a P/E ratio of -55.15 and a beta of 1.93.

Valneva (NASDAQ:VALN) last posted its quarterly earnings data on Wednesday, March 19th. The company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.32). Valneva had a negative net margin of 4.35% and a negative return on equity of 3.93%. The company had revenue of $56.48 million for the quarter, compared to analyst estimates of $55.64 million. As a group, equities analysts predict that Valneva will post 0.13 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Valneva stock. Wells Fargo & Company MN increased its holdings in shares of Valneva SE (NASDAQ:VALN) by 14.3% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 246,766 shares of the company’s stock after purchasing an additional 30,859 shares during the quarter. Wells Fargo & Company MN owned 0.30% of Valneva worth $1,079,000 as of its most recent filing with the SEC. 11.39% of the stock is currently owned by institutional investors.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.